section name header

Pronunciation ⬇

roe-SOO-va-sta-tin

Classifications ⬆ ⬇

Therapeutic Classification: lipid-lowering agents

Pharmacologic Classification: hmg coa reductase inhibitors (statins)

Indications ⬆ ⬇

REMS

Action ⬆ ⬇

  • Inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, an enzyme that is responsible for catalyzing an early step in the synthesis of cholesterol.
Therapeutic effects:
  • Lowering of total and LDL-C and triglycerides. Slightly increases HDL-C.
  • Slows the progression of coronary atherosclerosis.

Pharmacokinetics ⬆ ⬇

Absorption: 20% absorbed following oral administration.

Distribution: Unknown.

Metabolism/Excretion: 10% metabolized, 90% excreted unchanged in feces.

Half-Life: 19 hr.

Time/Action Profile ⬆ ⬇

(effect on lipids)

ROUTEONSETPEAKDURATION
POunknown2–4 wkunknown



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: rash

Endo: hyperglycemia

GI: abdominal pain, constipation, drug-induced hepatitis, ↑liver enzymes, nausea

Hemat: thrombocytopenia

MS: immune-mediated necrotizing myopathy, myalgia, RHABDOMYOLYSIS

Neuro: amnesia, confusion, memory loss, weakness

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Renal Impairment

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Crestor

Pill Image

rosuvastatin-calcium_195-8651.jpg

Code ⬆

NDC Code